Answers are grounded in this paper and cite their sources.
Withholding intravenous (IV) iron to treat iron-deficiency anemia (IDA) is a common practice in patients hospitalized with acute bacterial infection, driven by the theoretical risk from in vitro studies that iron may support bacterial growth. However, IV iron administration is beneficial for multiple patient populations with IDA, such as heart failure with reduced ejection fraction, chronic kidney disease, inflammatory bowel disease, and malignancy. Additionally, recent data suggest that administering IV iron in patients with infections does not worsen clinical outcomes. Routine withholding of IV iron in patients with adequately controlled infections should be avoided.
No takes yet. Share an insight, caveat, or question.
Cool et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: